In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously received at least one platinum-based chemotherapy regimen to receive ...

This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy ...

Patients were randomly assigned 1:1 to receive either pembrolizumab 200mg intravenously every 3 weeks with lenvatinib 20mg orally once daily or an investigator’s choice of chemotherapy ...

SAN FRANCISCO — Lenvatinib plus pembrolizumab did not ... of patients ineligible for cisplatin or any platinum-based chemotherapy. Data derived fromLoriot Y, et al. Abstract 432.

Opens in a new tab or window SAN DIEGO -- A combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) failed to meet survival endpoints compared with chemotherapy as first-line therapy for ...

Among more than 800 patients previously treated with platinum-based chemotherapy, the median progression-free survival (PFS) reached 7.2 months with pembrolizumab (Keytruda) plus lenvatinib ...

Please provide your email address to receive an email when new articles are posted on . Lenvatinib plus pembrolizumab conferred significantly longer PFS and OS than chemotherapy among women with ...

The researchers found that longer median progression-free survival occurred with lenvatinib plus pembrolizumab than with chemotherapy (overall: 7.2 versus 3.8 months; hazard ratio, 0.56 ...